GSK plc(GSK)Earnings, Financials & Key RatiosGSK plc (GSK) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the stock trades at a compelling 7.15 P/E TTM, the erratic nature of quarterly earnings and the 0.79 current ratio warrant caution regarding near-term liquidity and litigation-related volatility.
GSK plc (GSK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
GSK plc (GSK) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.24vs $1.16+6.9% | $10.3Bvs $10.2B+0.7% |
| Q1 2026 | Feb 4, 2026 | $0.68vs $0.64+6.3% | $11.8Bvs $11.4B+3.2% |
| Q4 2025 | Oct 29, 2025 | $1.48vs $1.26+17.5% | $8.5Bvs $8.5B+0.8% |
| Q3 2025 | Jul 30, 2025 | $0.96 | $10.9B |
Recent stock market news and headlines for GSK plc (GSK)
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and Jemperli, I believe Exdensur could become another meaningful growth driver.
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone payments and royalties from GSK, with potential annual earnings of ~$50m and upside if Utebzi achieves blockbuster status. Despite a volatile share price and limited pipeline, SPRO's low burn rate and funding runway into 2028 support a 'buy the dip' thesis for risk-tolerant investors.
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This app.
Key metrics vs top competitors for GSK plc (GSK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $53.32 | $107.23B | 7.16 | 4.11% | 17.5% | 39.4% | 6.12% | |
| $193.12 | $299.39B | 29.53 | 8.63% | 17.19% | 22.24% | — | |
| $157.03 | $299.63B | 21.84 | 5.97% | 24.14% | 31.42% | — | |
| $42.98 | $103.34B | 11.75 | 5.49% | 16.72% | 10.78% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — |
GSK plc (GSK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GSK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GSK plc (GSK) stock FAQ — growth, dividends, profitability & financials explained
GSK plc (GSK) reported $33.34B in revenue for fiscal year 2025. This represents a 300% increase from $8.34B in 1996.
GSK plc (GSK) grew revenue by 4.1% over the past year. Growth has been modest.
Yes, GSK plc (GSK) is profitable, generating $6.40B in net income for fiscal year 2025 (17.5% net margin).
Yes, GSK plc (GSK) pays a dividend with a yield of 6.12%. This makes it attractive for income-focused investors.
GSK plc (GSK) has a return on equity (ROE) of 39.4%. This is excellent, indicating efficient use of shareholder capital.
GSK plc (GSK) generated $7.37B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
